Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Astrazeneca Plc ADR (AZN)

Astrazeneca Plc ADR (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 151,281,536
  • Shares Outstanding, K 2,624,593
  • Annual Sales, $ 26,617 M
  • Annual Income, $ 3,196 M
  • 60-Month Beta 0.56
  • Price/Sales 5.60
  • Price/Cash Flow 17.71
  • Price/Book 10.44
Trade AZN with:

Options Overview

Details
  • Implied Volatility 20.40%
  • Historical Volatility 24.03%
  • IV Percentile 4%
  • IV Rank 6.07%
  • IV High 47.36% on 02/03/21
  • IV Low 18.65% on 06/15/21
  • Put/Call Vol Ratio 0.65
  • Today's Volume 3,391
  • Volume Avg (30-Day) 14,593
  • Put/Call OI Ratio 0.64
  • Today's Open Interest 316,382
  • Open Int (30-Day) 278,729

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 0.45
  • Number of Estimates 4
  • High Estimate 0.46
  • Low Estimate 0.43
  • Prior Year 0.48
  • Growth Rate Est. (year over year) -6.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
56.00 +2.36%
on 07/19/21
60.93 -5.92%
on 07/12/21
-2.58 (-4.31%)
since 06/30/21
3-Month
52.74 +8.68%
on 05/04/21
60.93 -5.92%
on 07/12/21
+4.25 (+8.01%)
since 04/30/21
52-Week
46.48 +23.32%
on 03/04/21
60.93 -5.92%
on 07/12/21
-0.57 (-0.98%)
since 07/30/20

Most Recent Stories

More News
Pharma Stock Roundup: Q2 Earnings of MRK, PFE & Others, FDA Approvals for GSK, ABBV

Pfizer (PFE), Merck (MRK) and others announce Q2 results. FDA approves AbbVie's (ABBV) new antibiotic injection and expands use of Merck's Keytruda and Glaxo's Shingrix and Nucala.

SNY : 51.54 (+0.02%)
AZN : 57.35 (-0.50%)
GSK : 40.10 (-0.07%)
PFE : 42.89 (+0.23%)
MRK : 77.40 (+0.61%)
LLY : 244.70 (-0.26%)
ABBV : 117.55 (-1.11%)
Emergent (EBS) Misses on Q2 Earnings, to Restart Bayview Unit

Emergent's (EBS) second-quarter 2021 earnings miss estimates. Revenues also fail to meet expectations. Stock down.

AZN : 57.35 (-0.50%)
JNJ : 172.44 (+0.15%)
CDXS : 21.35 (+0.09%)
EBS : 66.69 (+2.25%)
AstraZeneca (AZN) Q2 Earnings In Line, Vaccine Aids Sales

AstraZeneca (AZN) surpasses second-quarter estimates for revenues while earnings meet estimates. Stock up in pre-market.

AZN : 57.35 (-0.50%)
MRK : 77.40 (+0.61%)
CDXS : 21.35 (+0.09%)
ARVN : 100.75 (-6.60%)
Merck (MRK) Q2 Earnings Miss, Sales Rebound, Stock Slips

Merck (MRK) misses Q2 estimates for earnings but beats the same for sales. Stock down in pre-market.

AZN : 57.35 (-0.50%)
BMRN : 77.65 (-1.10%)
MRK : 77.40 (+0.61%)
OGN : 29.09 (-0.48%)
Astrazeneca: Q2 Earnings Snapshot

CAMBRIDGE, Britain (AP) _ Astrazeneca PLC (AZN) on Thursday reported second-quarter profit of $550 million.

AZN : 57.35 (-0.50%)
Telefonaktiebolaget LM Ericsson (NASDAQ: ERIC) Signs Its Biggest Deal Yet of $8.3 billion with Verizon Communications Inc. (NYSE: VZ)

NOK : 6.09 (+0.66%)
NDAQ : 187.47 (+0.42%)
AZN : 57.35 (-0.50%)
ERIC : 11.49 (+0.15%)
VZ : 55.97 (-0.02%)
Dyadic Int'l (DYAI) Inks Deal Toward Potential Access to 40% of the World as Covid Vaccine Continues in Development

NVAX : 182.19 (-0.98%)
MRNA : 357.48 (+3.43%)
PFE : 42.89 (+0.23%)
JNJ : 172.44 (+0.15%)
BNTX : 323.71 (+3.56%)
AZN : 57.35 (-0.50%)
IBB : 166.63 (+0.50%)
DYAI : 3.75 (+3.88%)
Merck (MRK) to Report Q2 Earnings: What's in the Cards?

Investor focus is likely to be on the sales numbers of Merck's (MRK) blockbuster oncology medicine, Keytruda.

AZN : 57.35 (-0.50%)
PFE : 42.89 (+0.23%)
MRK : 77.40 (+0.61%)
OGN : 29.09 (-0.48%)
What's in the Cards for AstraZeneca (AZN) in Q2 Earnings?

AstraZeneca's (AZN) second-quarter results are expected to reflect the impact of strong demand for new drugs. Investors are likely to focus on an updated guidance after Alexion acquisition.

AZN : 57.35 (-0.50%)
PFE : 42.89 (+0.23%)
MRK : 77.40 (+0.61%)
ABBV : 117.55 (-1.11%)
BYDUREON BCise (exenatide extended-release) Approved in the US for the Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Older

AstraZeneca's BYDUREON BCise (exenatide extended-release), once-weekly injectable suspension has been approved in the US for the treatment of type 2 diabetes (T2D); to improve glycemic control in pediatric...

AZN : 57.35 (-0.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development,...

See More

Key Turning Points

3rd Resistance Point 59.42
2nd Resistance Point 59.01
1st Resistance Point 58.32
Last Price 57.35
1st Support Level 57.23
2nd Support Level 56.82
3rd Support Level 56.14

See More

52-Week High 60.93
Last Price 57.35
Fibonacci 61.8% 55.41
Fibonacci 50% 53.71
Fibonacci 38.2% 52.00
52-Week Low 46.48

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar